Previous 10 | Next 10 |
What to Know About Trading Penny Stocks on April 11th With another week of trading penny stocks getting off to an interesting start, there is a lot for investors to know. Considering that there is still an extremely high amount of volatility in the stock market, investors need to be on ...
Veru (VERU) +31% after interim results for COVID-19 therapy. SailPoint Technologies (SAIL) +30% acquisition could lead to other cyber security deals, Wedbush says. Iveda Solutions (IVDA) +28%. VNET Group (VNET) +20% receives buyout offer of $1.3333 per share. Aff...
AIM ImmunoTech (NYSE:AIM) has added ~23% in the pre-market Monday after the clinical-stage biotech shared data for its cancer candidate Ampligen from trials targeted at metastatic triple-negative breast cancer and colorectal cancer. The ongoing Phase 2a trial for colorectal cancer m...
Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be useful to enhance effectiveness of immunotherapies Data from clinical research conducted at Roswell Park Comprehensiv...
Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint Positive data from this proof-of-concept study demonstrate that short-term systemic CKM followed by pembrol...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
AIM ImmunoTech press release (NYSE:AIM): FY GAAP EPS of -$0.04. As of December 31, 2021, AIM reported cash and cash equivalents of $48.3 million, compared to $54.4 million as of December 31, 2020. For further details see: AIM ImmunoTech GAAP EPS of -$0.04
- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen ® in multiple high-value indications - Company expected to continue advancing oncology-focused pipeline and well po...
OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...